{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T06:38:23Z","timestamp":1725863903809},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clinthera.2013.06.012","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T14:47:16Z","timestamp":1375368436000},"page":"1174-1185.e4","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Tolerability Exposure\u2013Response Relationship of Retigabine (Ezogabine) Immediate-Release Tablets in Patients With Partial-Onset Seizures"],"prefix":"10.1016","volume":"35","clinical-trial-number":[{"clinical-trial-number":"nct00232596","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00235755","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Debra J.","family":"Tompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Crean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Seth","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.06.012_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3458.2005.tb00033.x","article-title":"Retigabine: chemical synthesis to clinical application","volume":"11","author":"Blackburn-Munro","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.clinthera.2013.06.012_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0920-1211(95)00101-8","article-title":"D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures","volume":"23","author":"Rostock","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2013.06.012_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-2999(96)00073-8","article-title":"D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures","volume":"303","author":"Tober","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0014-2999(97)01249-1","article-title":"The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells","volume":"336","author":"Rundfeldt","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-2999(99)00786-4","article-title":"Retigabine strongly reduces repetitive firing in rat entorhinal cortex","volume":"386","author":"Hetka","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/mol.58.2.253","article-title":"Modulation of KCNQ2\/3 potassium channels by the novel anticonvulsant retigabine","volume":"58","author":"Main","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/mol.58.3.591","article-title":"Retigabine, a novel anti-convulsant, enhances activation of KCNQ2\/Q3 potassium channels","volume":"58","author":"Wickenden","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib8","first-page":"1063","article-title":"Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels","volume":"50","author":"Rundfeldt","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2013.06.012_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3940(00)00866-1","article-title":"The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2\/3 subunits","volume":"282","author":"Rundfeldt","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2013.06.012_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0920-1211(01)00193-0","article-title":"Effects of retigabine on rhythmic synchronous activity of human neocortical slices","volume":"44","author":"Straub","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2013.06.012_bib11","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001","article-title":"Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine","volume":"21","author":"Tatulian","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2013.06.012_bib12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1124\/mol.61.4.921","article-title":"Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission","volume":"61","author":"Otto","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1113\/jphysiol.2003.039842","article-title":"Effect of the KCNQ potassium channel opener retigabine on single KCNQ2\/3 channels expressed in CHO cells","volume":"549","author":"Tatulian","year":"2003","journal-title":"J Physiol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib14","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1523\/JNEUROSCI.0765-04.2004","article-title":"KCNQ\/M channels control spike after depolarization and burst generation in hippocampal neurons","volume":"24","author":"Yue","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2013.06.012_bib15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1523\/JNEUROSCI.4512-03.2004","article-title":"KCNQ2 is a nodal K+ channel","volume":"24","author":"Devaux","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2013.06.012_bib16","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1073\/pnas.0603376103","article-title":"Polarized axonal surface expression of neuronal KCNQ channels is mediated by multiple signals in the KCNQ2 and KCNQ3 C-terminal domains","volume":"103","author":"Chung","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2013.06.012_bib17","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1523\/JNEUROSCI.4314-05.2006","article-title":"A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon","volume":"26","author":"Pan","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2013.06.012_bib18","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/j.1528-1167.2008.01674.x","article-title":"Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study","volume":"49","author":"Mazarati","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2013.06.012_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1124\/mol.108.049825","article-title":"Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention","volume":"74","author":"Mackie","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2007.11.010","article-title":"Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds","volume":"29","author":"Xiong","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2013.06.012_bib21","first-page":"557","article-title":"Potassium channels: molecular defects, diseases, and therapeutic opportunities","volume":"52","author":"Shieh","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2013.06.012_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bjp.0703861","article-title":"Characterization of KCNQ5\/Q3 potassium channels expressed in mammalian cells","volume":"132","author":"Wickenden","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/00912700222011210","article-title":"Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers","volume":"42","author":"Ferron","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.012_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mcp.2003.12","article-title":"Effects of age and sex on the disposition of retigabine","volume":"73","author":"Hermann","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.06.012_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.metabol.2006.01.006","article-title":"N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II","volume":"55","author":"Borlak","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2013.06.012_bib26","unstructured":"Glaxo Group Limited. Trobalt film-coated tablets: summary of product characteristics [online]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001245\/WC500104835.pdf. Accessed August 7, 2012."},{"key":"10.1016\/j.clinthera.2013.06.012_bib27","first-page":"A331","article-title":"An early determination of drug-drug interaction between valproic acid, phenytoin, carbamazepine or topiramate, and retigabine in epileptic patients","volume":"56","author":"Sachdeo","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2013.06.012_bib28","first-page":"613","article-title":"Metabolism of retigabine (D-23129), a novel anticonvulsant","volume":"27","author":"Hempel","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2013.06.012_bib29","first-page":"114","article-title":"Effect of hepatic impairment on retigabine pharmacokinetics","volume":"49","author":"Mansbach","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2013.06.012_bib30","first-page":"116","article-title":"Effect of renal impairment of retigabine pharmacokinetics","volume":"49","author":"Shin","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2013.06.012_bib31","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"On behalf of the RESTORE 1\/Study 301 Investigators. Randomized double-blind placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2013.06.012_bib32","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2013.06.012_bib33","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2013.06.012_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0378-4347(00)00272-3","article-title":"Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry","volume":"748","author":"Knebel","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.clinthera.2013.06.012_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF01060053","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters I. Michaelis-Menten model: routine clinical pharmacokinetic data","volume":"8","author":"Sheiner","year":"1980","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2013.06.012_bib36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF01061030","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2013.06.012_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01061870","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters III. Monoexponential model: routine clinical pharmacokinetic data","volume":"11","author":"Sheiner","year":"1983","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2013.06.012_bib38","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry. Population Pharmacokinetics. 1999. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072137.pdf. Accessed August 10, 2012."},{"key":"10.1016\/j.clinthera.2013.06.012_bib39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2008.00633.x","article-title":"The Hill equation: a review of its capabilities in pharmacological modelling","volume":"22","author":"Goutelle","year":"2008","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T05:52:10Z","timestamp":1563601930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813003408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0149291813003408"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.06.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}